WorldWide Cancer Gene Therapy Market, Industry / Sector Analysis Report, Regional Outlook & Competitive Market Share & Forecast, 2019 - 2025 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Cancer Gene Therapy Market

Industry / Sector Trends

Cancer Gene Therapy Market size was USD 805.5 million in 2015, with 20.7% CAGR estimation from 2016 to 2024.
 

U.S. Cancer Gene Therapy Market size, by type, 2012 - 2024 (USD Million)
 

Rapid technological advancements, increased adoption of emerging genomic technologies such as NGS and high-density micro array are some of the factors that will drive global cancer gene therapy market over the forecast period.
 

The rising prevalence of cancer is expected to increase the demand for genetherapy. In accordance with WHO, the number of new cases is projected to rise by 70% in next two decades. The tremendous growth in number of patients should fuel the industry growth.
 

Favorable government regulations will boost cancer genetics industry growth. For instance, Mainstreaming Cancer Genetics (MCG) programme aims to develop clinical infrastructure, assays, informatics, education and assessment that will allow gene testing of patients. The programme offers scalable and convenient tools for the integration of gene testing into mainstream medical practice across the NHS.
 

High development cost of drugs will act as an impediment to industry growth. It’s expensive to conduct clinical trials that includes expensive phase I, II and III for the approval. High cost of clinical trials will serve as a major bottleneck over the forecast time frame.
 

Market Segmentation, Outlook & Regional Insights: Cancer Gene Therapy Market

 Cancer Gene Therapy Market, By Therapy

Transfer cancer gene therapy market share was over 46% of global revenue in 2015 and is see growth of 20.9% throughout the forecast period.
 

Adenoviral vector is most commonly used oncology application due to its competent nuclear mechanism and low pathogenicity. Adenoviral vectors are used in gene replacement approaches, suicide gene, gene-based immunotherapy, and syndicate gene with chemotherapy; over 20% growth is forecast for this segment.
 

Retroviral vector-mediated gene transfer dominated the development of gene therapy industry. It provides most significant benefit of converting the single stranded RNA genome into a double stranded DNA molecule, which steadily integrates into the target cell genome. Retroviral vectors are used to permanently modify the host cell nuclear genome. It’s oncolytic actions are mostly through stimulation of the immune system. It will grow at 20.6% CAGR over the forecast period.
 

The gene induced immunotherapy is used for the treatment of cancer disease. It substitutes mutated gene with a healthy copy of gene. A newly developed technique of supplementing novel genes into the tumor that will help to fight against cancer cells is extensively used. Cancer gene induced immunotherapy market accounted for 14% of revenue share in 2015 and anticipated to exceed USD 592.7 million by 2024.
 

Cancer Gene Therapy Market, By Region

China cancer gene therapy market share is estimated to account for 35.4% of APAC revenue in 2015, being the first country to commercialize the gene therapy cancer drugs. Gendicine obtained license from the SFDA for its recombinant Ad-p53 gene therapy for head and neck squamous cell carcinoma. The increasing healthcare expenditure and robust R&D facilities will enable industry growth.
 

U.S. market contributes to 97.8% of regional revenue share in 2015, attributed to rise in the incidence and adoption of advanced treatments.
 

UK is contributing to majority of Europe cancer gene therapy market share in 2015 owing to rise in prevalence coupled with increased adoption of gene technology. Japan was valued over USD 78.2 million in 2015 and expanding at 20.9% CAGR from 2016 to 2024.
 

Key Players, Recent Developments & Sector Viewpoints: Cancer Gene Therapy Market


Major players include SiBiono., Shanghai Sunway Biotech company limited, Altor Bioscience Corporation, Amgen, BioCancell, Aduro Biotech, OncoGeneX, GlobeImmune, Inc., New Link Genetics., MolMed S.p.A, ZioPharm Oncology, Gradalis, GENELUX, MultiVir.
 

Small biotech firms dominate the global cancer gene therapy market. The players are constantly engaged in R&D in order to develop novel methods to treat various life-threatening diseases.
 

Cancer Gene Therapy Industry Background

Cancer genetics is novel treatment method marked by high costs of R&D. The therapy targets diseases with high unmet needs, this has been driving force behind academic research laboratories, small biotech firms and large pharmaceutical companies. The therapy is short duration treatment or mostly be one-time treatment customised to the individual, and often in small patient populations.
 

The current competitive landscape for cancer gene therapy is dominated by small pioneering biotech firms. The small players may enter into strategic collaborations with larger players to continue clinical development or commercialization of products. Manufacturers will take premium prices for the medicines. Lack of reimbursement policies for advanced gene therapy methods will hamper market growth

Key Insights Covered: Exhaustive Cancer Gene Therapy Market
1.  Market size (sales, revenue and growth rate) of Cancer Gene Therapy industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Cancer Gene Therapy industry.
3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Cancer Gene Therapy industry.
4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Cancer Gene Therapy industry.

Research Methodology: Cancer Gene Therapy Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.